Tuesday, February 14, 2017 9:48:34 AM
1095 is designed to bind to the extracellular domain of prostate specific membrane antigen (PSMA), a protein that is expressed in greater than 95% of prostate cancer cells, and upon binding, internalized by the prostate cancer cells where its iodine-131 beta particles kill the tumor cells. When administered under a compassionate use setting, 1095 was well tolerated and demonstrated markedly reduced PSA levels and bone pain in a group of heavily-pretreated advanced prostate cancer patients (N=28) following a single cycle of treatment.1
“MIP 1095 holds the promise of optimizing tumor-specific delivery of radiation, with the added potential benefit of rapid clearance of the molecule and its radioactive payload that can minimize radiation exposure to normal tissues,” said Michael J. Morris, MD of Memorial Sloan Kettering Cancer Center, and lead investigator of the study. “The totality of the preclinical and compassionate use data provides strong support for 1095 in metastatic castration-resistant prostate cancer, and I look forward to further evaluating this drug in the clinical setting.”
This Phase 1 open-label dose-escalation study will enroll approximately 40 patients with mCRPC who have demonstrated tumor avidity to 1095. The primary objectives of this study include determination of maximum tolerated dose, safety and tolerability, biodistribution, and efficacy. Findings from this trial will guide the decision of an optimal dose for a Phase 2 trial.
“The initiation of this trial reflects our commitment to advancing PSMA-targeted candidates that have the potential to transform how prostate cancer is detected, managed and treated,” said Mark Baker, CEO of Progenics. “The insights we gain from this trial will help guide the design of the future clinical development program of 1095.”
About 1095
Progenics’ small molecule therapeutic candidate 1095 is designed to bind to the extracellular domain of prostate specific membrane antigen (PSMA), a protein that is expressed in >95% of prostate cancer cells, and upon binding, to be internalized by the prostate cancer cells, where its iodine-131 beta particles kill the malignant cell. The ability to specifically deliver radiation to prostate cancer cells anywhere in the body allows a commonly used therapy (radiation) to be used with precision to attack systemic disease. Preclinical data has shown high tumor uptake and a favorable tumor to kidney discrimination yielding a lethal radiation dose to the tumor while minimizing normal tissue dose. In human prostate cancer mouse models, the compound, administered in single or multiple dose schedules, significantly reduced tumor burden for a prolonged period of time and enhanced survival with no significant signs of toxicity. When used in a compassionate use setting, 1095 markedly reduced PSA levels and bone pain in a group of 22 heavily-pretreated advanced prostate cancer patients.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM